Treatment Strategies in ANCA-Associated Vasculitis Abstract Purpose of Review The long-term survival of patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) has improved dramatically as a direct result of evolving therapy. This review summarizes evidence-based treatment strategies with currently approved immunosuppressive medications to serve as a guide for practitioners in the management of patients with AAV. Recent Findings Targeted therapy aimed at minimizing treatment-related adverse effects while optimizing effectiveness is a propagated approach. Such tailored therapy considers disease severity and is especially warranted in those at high risk for relapsing vasculitis. Summary As treatment options for AAV become available, the need to tailor therapy has become increasingly relevant to optimize patient outcomes.